Solana Company AI Stock Analysis
Want to see HSDT full AI Analyst Report?
Solana Company (HSDT) AI Stock Analysis
Solana Company
(NASDAQ:HSDT)
HSDT scores highest on financial positioning and valuation: a no-debt balance sheet and very low P/E support the stock, and the earnings call reinforced operational progress and scaling of staking infrastructure. Offsetting these positives are weak cash flow (negative operating and free cash flow) and poor technicals (price below key moving averages with negative MACD), which together increase risk and limit the overall score.
Solana Company (HSDT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $87.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 580.12K
- Price to Earnings (P/E)
- 0.4
- Beta (1Y)
- 0.86
- Revenue Growth
- 1465.89%
- EPS Growth
- ―
- Country
- US
- Employees
- 21
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Asset Management
Solana Company Business Overview & Revenue Model
Company Description
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies...
Solana Company Earnings Call Summary
The call was broadly positive, with management highlighting strong revenue growth, an 82% gross margin, reduced operating costs, a return to quarterly profitability, SOL treasury growth, above-network staking yields and faster-than-expected third-party delegation. The main challenges were the first-nine-month operating and net losses, realized digital asset losses, limited cash relative to obligations, potential expense normalization, moderating delegation growth and volatility in staking outperformance. The positive developments significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, the company plans to grow Pacific Backbone’s third-party stake, complete its assessment of Hong Kong as its next validated location, work with ISO 27001 certification targeted for the fourth quarter of 2026, use its planned new regional headquarters in Hong Kong to bring more institutions on to Solana and grow its staking offering, and keep compounding SOL per share; it said OpEx would “probably normalize between what our current rate is and what our historic rate, something in between,” while “as the business grows, we would expect an increase in expenses,” third-party stake growth from 300,000 to over 1 million SOL is “probably going to slow down a bit in the fourth quarter,” it does not expect it to reach “$3 million by the end of the quarter,” and by “first quarter next year” it expects more third parties to come to its validated infrastructure; management also said it “should be able to continue to outperform,” should maintain “some performance gap,” but that “gap might be volatile quarter-to-quarter.”
Solana Company Financial Statement Overview
Summary
Reported profitability improved sharply in the TTM period with strong revenue growth and very high margins, and the balance sheet is conservatively positioned with essentially no debt and substantial equity. However, cash generation is a major weakness: operating cash flow and free cash flow are negative in TTM, and the multi-year history of losses makes the durability and quality of the earnings turnaround less certain.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.73M | 6.02M | 520.00K | 644.00K | 787.00K | 522.00K |
| Gross Profit | 13.68M | 5.52M | -62.00K | 61.00K | 324.00K | 224.00K |
| EBITDA | 322.25M | -39.58M | -13.80M | -12.11M | -14.50M | -17.82M |
| Net Income | 300.66M | -40.89M | -11.74M | -8.85M | -14.07M | -18.13M |
Balance Sheet | ||||||
| Total Assets | 292.65M | 303.93M | 3.54M | 7.69M | 17.29M | 14.10M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 7.28M | 1.09M | 5.18M | 14.55M | 11.01M |
| Total Debt | 0 | 0 | 12.00K | 57.00K | 110.00K | 3,000 |
| Total Liabilities | 26.41M | 3.02M | 2.48M | 5.34M | 9.14M | 2.85M |
| Stockholders Equity | 266.24M | 300.91M | 1.06M | 2.35M | 8.15M | 11.26M |
Cash Flow | ||||||
| Free Cash Flow | -25.97M | -61.29M | -11.05M | -10.45M | -14.33M | -13.44M |
| Operating Cash Flow | -25.97M | -16.51M | -11.04M | -10.42M | -14.31M | -13.39M |
| Investing Cash Flow | -144.84M | -426.53M | -5,000 | -29.00K | -11.00K | -56.00K |
| Financing Cash Flow | 47.88M | 449.24M | 6.95M | 1.08M | 17.87M | 21.13M |
Solana Company Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSDT, the sentiment is Negative. The current price of 1.49 is below the 20-day moving average (MA) of 1.92, below the 50-day MA of 2.29, and below the 200-day MA of 2.02, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 24.09 is Positive, neither overbought nor oversold. The STOCH value of 17.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSDT.
Solana Company Risk Analysis
Solana Company disclosed 45 risk factors in its most recent earnings report. Solana Company reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSolana Company Peers Comparison
Overall Rating
VMD75Outperform
SGHT61Neutral
HSDT60Neutral
SNWV48Neutral
OM47Neutral
CVRX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $326.26M | 20.92 | 10.78% | ― | 21.81% | 17.67% | |
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| 61Neutral | $590.25M | -19.64 | -51.66% | ― | 16.23% | 41.47% | |
| 60Neutral | $104.39M | 0.39 | 129.22% | ― | 1465.89% | ― | |
| 48Neutral | $13.68M | 5.00 | 113.13% | ― | -0.61% | ― | |
| 47Neutral | $54.86M | -0.73 | -68.03% | ― | 1.58% | 70.22% | |
| 37Underperform | $15.18M | -0.25 | -208.45% | ― | 7.79% | 0.87% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HSDT | Solana Company | 1.49 | -2.26 | -60.27% | |
| SNWV | Sanuwave Health Inc. | 1.50 | -32.27 | -95.56% | |
| VMD | Viemed Healthcare US | 8.52 | 1.66 | 24.20% | |
| OM | Outset Medical, Inc. | 2.81 | -1.52 | -35.10% | |
| CVRX | Cvrx, Inc. | 0.50 | -9.34 | -94.91% | |
| SGHT | Sight Sciences, Inc. | 10.18 | 2.69 | 35.91% |
Solana Company Corporate Events
Solana Company Announces Premium-Priced Equity Offering
PositiveOn September 30, 2026, Solana Company priced a $15 million registered direct offering with a single global institutional investor, selling 4,369,356 Class A shares at $3.433 each alongside equal-count warrants exercisable at $3.776 per share, both st...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
